Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Growth in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 45,910 shares, an increase of 55.9% from the July 15th total of 29,440 shares. Based on an average daily trading volume, of 25,260 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.1% of the shares of the company are sold short.

Barinthus Biotherapeutics Stock Up 0.8%

Shares of BRNS opened at $0.62 on Thursday. The company has a 50-day moving average price of $0.63 and a two-hundred day moving average price of $0.63. The stock has a market cap of $25.53 million, a price-to-earnings ratio of -0.61 and a beta of -0.39. Barinthus Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Barinthus Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Trading of Barinthus Biotherapeutics

A number of large investors have recently bought and sold shares of BRNS. Baird Financial Group Inc. raised its stake in Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after purchasing an additional 76,800 shares in the last quarter. Finally, Rangeley Capital LLC grew its holdings in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after purchasing an additional 75,024 shares during the last quarter. 25.20% of the stock is currently owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.